Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Cardiovascular risk reduction in diabetes
Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Time-critical presentation
New chest pressure, acute dyspnoea, focal neurological deficit, syncope with instability or a cold painful limb requires the relevant emergency pathway. Diabetes can make ischaemic presentations less typical; prevention review must never delay ECG, troponin, stroke assessment, resuscitation or urgent vascular input.
Role and principles
Integrate vascular risk assessment and evidence-based prevention for adults with diabetes without reducing care to a single score or medicine.
Diabetes increases coronary, cerebrovascular, peripheral arterial and heart-failure risk, but that risk is heterogeneous. Duration, age, smoking, blood pressure, kidney disease, albuminuria, lipid profile, family history and existing end-organ damage all change the absolute benefit of intervention. A useful consultation therefore starts by defining whether this is secondary prevention, primary prevention with a recognised high-risk condition, or score-based primary prevention.
Risk modification is cumulative. Smoking cessation, appropriate lipid lowering, controlled blood pressure, kidney protection and treatment choices with proven cardiorenal benefit can reinforce one another. Very tight pursuit of one biomarker at the expense of hypoglycaemia, postural symptoms, frailty, polypharmacy or treatment burden is not person-centred prevention.
Use live NICE pathways, the product licence and the local formulary. Pregnancy, advanced kidney or liver disease, transplant status, type 1 diabetes, recurrent hypoglycaemia and complex multimorbidity warrant tailored specialist or multidisciplinary decisions.
Key points
Separate primary prevention from established cardiovascular disease because risk scoring, antithrombotic treatment and lipid intensity are not interchangeable between those settings.
Assessment and patient selection
Established vascular disease
Previous myocardial infarction, angina, coronary or peripheral revascularisation, ischaemic stroke, transient ischaemic attack or symptomatic peripheral arterial disease places the person on a secondary-prevention pathway rather than a risk-score threshold.
Possible occult ischaemiaRed flag
Exertional breathlessness, unexplained falls, epigastric pressure or reduced exercise tolerance may be an anginal equivalent, especially with autonomic neuropathy; investigate symptoms clinically rather than arranging routine screening of every asymptomatic adult.
Heart-failure phenotypeRed flag
Orthopnoea, oedema, raised jugular venous pressure, crackles or a displaced apex should trigger diagnostic assessment because heart failure materially changes diabetes-drug selection and prognosis.
Kidney-amplified risk
Reduced estimated GFR or persistent albuminuria signals vascular and renal risk even when creatinine appears modest; verify chronicity and quantify urinary albumin rather than relying on dipstick protein alone.
Treatment toxicity
Postural dizziness, muscle symptoms, recurrent hypoglycaemia, genital infection, volume depletion or worsening renal indices may reflect treatment harm and should prompt structured review instead of unsupervised discontinuation.
Peripheral arterial diseaseRed flag
Exertional calf pain, rest pain, non-healing wounds, tissue loss or absent pulses require vascular assessment; a threatened limb needs same-day escalation and must not wait for a routine diabetes review.
Baseline assessment
01Structured cardiovascular history and examinationFirst step
Why
Define secondary-prevention disease, current symptoms and modifiable exposures before calculating risk.
Interpretation and limitations
Record smoking, family history, activity, diet, adherence, sitting and standing pressure where indicated, pulse rhythm, heart-failure signs and peripheral circulation; symptoms override a reassuring numerical score.
02Non-fasting lipid profile
Why
Establish baseline atherogenic burden and measure response to lipid-lowering treatment.
Interpretation and limitations
Review total, HDL and non-HDL cholesterol with triglycerides; markedly raised triglycerides or possible familial hypercholesterolaemia requires a specific pathway rather than routine statin titration alone.
03Renal profile and urine albumin:creatinine ratio
Why
Identify chronic kidney disease, albuminuria and prescribing constraints with prognostic importance.
Interpretation and limitations
Repeat unexpected abnormalities in the appropriate timeframe, distinguish acute kidney injury from chronic disease, and use both estimated GFR and albumin category for risk and treatment planning.
04HbA1c and hypoglycaemia review
Why
Assess glycaemic exposure while identifying whether intensification would create disproportionate harm.
Interpretation and limitations
Interventions
01ClassifyDefine the prevention settingFirst stepAn adult with diabetes attends cardiovascular or annual long-term-condition review.+
1Search the record and history for coronary, cerebrovascular and peripheral arterial disease, heart failure, chronic kidney disease, albuminuria and previous revascularisation.
2If no established disease is present, use the current NICE primary-prevention framework, including the special recommendations for type 1 diabetes and conditions in which risk may be underestimated.
3Document the category and rationale so subsequent prescribers do not inadvertently substitute score-based primary prevention for a secondary-prevention plan.
02OptimiseBuild a combined intervention planAssessment identifies one or more modifiable vascular risks or incomplete protective treatment.+
Medicines and treatment safety
Reduces atherosclerotic events as part of combined risk management rather than replacing smoking, pressure or kidney intervention.
Atorvastatin for primary prevention
NICE recommends atorvastatin 20 mg once daily when its current primary-prevention criteria are met; confirm pregnancy status, interactions, baseline assessment and the live formulary before prescribing.
Review unexplained active liver disease, pregnancy and breastfeeding, interacting medicines and severe muscle symptoms. Follow NICE advice on baseline transaminases, symptom-led creatine kinase testing and response monitoring; do not stop for a trivial isolated laboratory change without applying the guideline.
May provide glucose, heart-failure and kidney benefit in selected adults whose comorbidity matches the current treatment pathway.
SGLT2 inhibitor class
Select the individual licensed product and dose from current NICE recommendations, renal thresholds, SmPC and local formulary; there is no safe universal class dose for every indication.
Explain genital infection, volume-depletion and ketoacidosis risks, including euglycaemic presentations. Pause according to current sick-day, major-surgery and acute-serious-illness guidance, use blood ketones when indicated, and involve diabetes or renal specialists when type, kidney function or prior ketoacidosis makes use uncertain.
Targets, monitoring and follow-up
Record smoking status, blood pressure, weight trajectory, lipid profile, HbA1c, estimated GFR and albuminuria at intervals determined by abnormality, treatment and current NICE guidance.
After starting or changing a lipid-lowering medicine, reassess adherence, adverse effects and lipid response at the guideline-specified review rather than waiting automatically for the next annual appointment.
Check creatinine and potassium at the locally specified interval after initiating or increasing an ACE inhibitor, angiotensin-receptor blocker or mineralocorticoid-relevant regimen, with action thresholds taken from the current renal pathway.
Review orthostatic symptoms, falls and home or ambulatory pressure data when clinic readings, autonomic neuropathy or frailty make aggressive pressure lowering potentially hazardous.
For an SGLT2 inhibitor, revisit hydration, foot and genital symptoms, acute-illness rules, ketone advice and renal function; suspected ketoacidosis requires immediate cessation and acute assessment.
Use each admission, retinal or renal review and medicines reconciliation as an opportunity to identify missing secondary-prevention therapy and arrange ownership of follow-up.
Special situations
A score is not a diagnosis
Risk calculators support shared primary-prevention decisions but can be distorted by missing data and do not replace recognition of symptomatic or established vascular disease.
Non-HDL supports follow-through
Using the same lipid metric before and after treatment makes response visible and helps distinguish non-adherence, inadequate intensity and an unusual lipid disorder.
Cardiorenal selection matters
A glucose-lowering agent may be chosen partly for heart or kidney outcome evidence, so a satisfactory HbA1c alone should not end the comorbidity review.
Primary aspirin can harm
Diabetes by itself is not a routine indication for antiplatelet primary prevention because bleeding can outweigh benefit; document the actual vascular indication.
Pregnancy changes prevention
Statins and renin–angiotensin system medicines require preconception and pregnancy review; ask rather than assuming contraception or future pregnancy intentions.
Inequality changes delivery
Language, health literacy, medication cost, food access, disability and appointment access influence risk outcomes; provide accessible information and practical follow-up rather than recording non-compliance.
Common pitfalls
01
Calculating QRISK for someone with a previous myocardial infarction and then withholding secondary prevention because the displayed number seems low.
02
Starting several protective medicines without documenting indication, monitoring, sick-day advice or which clinician will review intolerance and laboratory results.
03
Treating a low HbA1c as proof of safety while overlooking insulin-associated hypoglycaemia, renal decline, weight loss or frailty.
04
Using aspirin routinely in uncomplicated diabetes despite the absence of a recognised antiplatelet indication and an individual bleeding assessment.
05
Stopping a statin permanently after non-specific aches without assessing temporal relation, interactions, creatine kinase when indicated or a tolerated alternative regimen.
06
Missing heart failure or peripheral arterial disease because the consultation remains confined to blood pressure, lipids and glucose values.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA
Secondary prevention classification
A 59-year-old woman with type 2 diabetes and a previous ischaemic stroke attends annual review. Her calculated ten-year cardiovascular score is below the local primary-prevention threshold. What is the best interpretation?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Address smoking, blood pressure, atherogenic lipids, albuminuria, glycaemia, weight, physical activity and medicines adherence as one longitudinal plan rather than isolated annual-review boxes.
Use the current NICE risk-assessment method where it applies, but do not use a calculated score to downgrade people who already have cardiovascular disease or another high-risk condition.
Offer statin treatment according to the current NICE prevention pathway after discussing benefit, pregnancy potential, adverse effects, interactions and the person’s priorities.
Choose glucose-lowering treatment with heart failure, atherosclerotic disease and chronic kidney disease in view; cardiorenal benefit may matter independently of the glucose result.
Do not prescribe aspirin solely because a person has diabetes; antiplatelet treatment follows a documented secondary-prevention or other specific indication.
Confirm persistent albuminuria and optimise renal and blood-pressure protection while checking creatinine, estimated GFR and potassium after relevant renin–angiotensin system changes.
Make the plan measurable: record baseline values, treatment targets, safety monitoring, sick-day advice and a named review point for incomplete response or intolerance.
Interpret the value alongside glucose records, anaemia, haemoglobinopathy, kidney disease, frailty and previous severe episodes; an apparently favourable HbA1c can conceal frequent hypoglycaemia.
05ECG and symptom-directed cardiac testing
Why
Investigate suspected arrhythmia, ischaemia or structural disease rather than screening indiscriminately.
Interpretation and limitations
An abnormal ECG may support urgent referral, but a normal resting tracing does not exclude acute coronary syndrome or exertional angina when the clinical story remains concerning.
06QRISK assessment when eligible
Why
Estimate ten-year primary-prevention risk using the current NICE-endorsed approach.
Interpretation and limitations
Use a current validated calculator and accurate inputs; do not apply it as a veto in established cardiovascular disease, very high-risk conditions or situations where NICE recommends treatment without scoring.
1
Agree priorities with the person, offering behavioural support for tobacco dependence, activity, diet, weight and alcohol while avoiding blame or an unmanageable list of simultaneous changes.
2Apply the current NICE lipid and blood-pressure pathways, check interactions and organ function, and identify a cardiorenal rationale for glucose-lowering choices rather than focusing only on HbA1c.
3Set explicit monitoring and response criteria, including what to do during dehydration or acute illness and when adverse effects require urgent advice rather than permanent self-discontinuation.
03EscalateRespond to inadequate control or intoleranceEscalationTargets remain unmet, adverse effects occur, or comorbidity makes the standard sequence unsuitable.+
1First verify adherence, dosing, timing, secondary causes and lifestyle barriers, and repeat measurements rather than labelling treatment failure from a single result.
2EscalationFollow the live NICE escalation pathway for lipid, hypertension, kidney and diabetes therapy; use the local formulary and obtain specialist advice for complex interactions, severe organ dysfunction or suspected familial dyslipidaemia.
3Record the replacement strategy and follow-up date whenever a medicine is reduced or stopped so therapeutic inertia does not leave the vascular risk untreated.
04EmergencyDo not medicalise acute vascular symptoms as risk reviewThe person reports current chest pain, acute focal neurology, decompensated heart failure or threatened-limb features.+
1Use an ABCDE approach, obtain time-critical observations and bedside glucose, and activate the appropriate acute coronary, stroke, heart-failure or vascular service without waiting for routine blood results.
2Reconcile diabetes medicines during acute illness, protecting against hypoglycaemia, ketoacidosis, renal injury and contrast-related prescribing hazards through the relevant local protocol.
3After stabilisation, ensure the discharge plan clearly assigns secondary-prevention medicines, rehabilitation, safety-netting and early follow-up across hospital and primary-care teams.